The rise in lifestyle-related conditions like low blood
pressure, diabetes, obesity, and aging, along with the growing
incidence of venous thromboembolism, cardiovascular diseases,
cancer, and neurological disorders such as ischemic stroke,
hemorrhagic stroke, and peripheral diseases, is driving up the need
for thrombectomy devices.
LAS VEGAS, June 4, 2024 /PRNewswire/ -- DelveInsight's
Thrombectomy Devices Market Insights report provides
the current and forecast market analysis, individual leading
thrombectomy devices companies' market shares, challenges,
thrombectomy devices market drivers, barriers, trends, and key
market thrombectomy devices companies in the market.
Key Takeaways from the Thrombectomy Devices Market
Report
- As per DelveInsight estimates, North
America is anticipated to dominate the global thrombectomy
devices market during the forecast period.
- In the product segment of the thrombectomy devices market, the
mechanical thrombectomy category had a significant revenue share in
the year 2023. This can be ascribed to the applications and
advantages related to the segment.
- Notable thrombectomy devices companies such as Koninklijke
Philips N.V., Terumo Corporation, Medtronic, Boston Scientific
Corporation, Penumbra, Inc., Thrombolex, Imperative Care Inc.,
Stryker, Argon Medical Devices Inc., Edwards Lifesciences
Corporation, Johnson & Johnson, BD, phenox GmbH, DSMAREF
CO.LTD, Teleflex Incorporated, AngioDynamics, Abbott, inari
Medical, Merit Medical Systems, Acandis GmbH, and several
others, are currently operating in the thrombectomy devices
market.
- In September 2022, Vesalio
announced European CE Mark approval of the company's NeVa Net thrombectomy device, which features
integrated clot microfiltration technology.
- In September 2021, Abbott
acquired Walk Vascular, LLC, a commercial-stage medical device
company with a minimally invasive mechanical aspiration
thrombectomy system designed to remove peripheral blood clots. Walk
Vascular's peripheral thrombectomy systems will be incorporated
into Abbott's existing endovascular product portfolio.
- In May 2020, Control Medical
Technology obtained the US Food and Drug Administration (FDA)
approval for its Aspire MAX 7 – 11F Mechanical Thrombectomy
platform. Aspire MAX 7 – 11F Mechanical Thrombectomy platform has
been designed to remove blood clots from the peripheral
vessels.
To read more about the latest highlights related to the
thrombectomy devices market, get a snapshot of the key highlights
entailed in the Global Thrombectomy Devices Market
Report
Thrombectomy Devices Overview
Thrombectomy devices represent a groundbreaking advancement in
the field of interventional medicine, offering a minimally invasive
solution for treating stroke and other vascular occlusions. These
devices are engineered to swiftly and effectively remove blood
clots from arteries, restoring blood flow to the affected area and
mitigating the risk of debilitating neurological damage. Utilizing
innovative techniques such as aspiration and stent retrievers,
thrombectomy devices enable clinicians to rapidly intervene in
acute ischemic stroke cases, significantly improving patient
outcomes and reducing long-term disability.
The evolution of thrombectomy devices has revolutionized stroke
care, extending the therapeutic window for treatment and expanding
access to critical interventions. With enhanced maneuverability and
imaging guidance, these devices empower clinicians to navigate
complex vascular anatomy precisely, optimizing outcomes for
patients facing life-threatening thrombotic events. As ongoing
research continues to refine these technologies and broaden their
applicability, thrombectomy devices stand as a beacon of hope in
the fight against stroke, offering a transformative approach to
restoring neurological function and preserving the quality of
life.
Thrombectomy Devices Market Insights
In 2023, North America led the
thrombectomy devices market due to various factors. These include
the region's high prevalence of conditions like cancer,
neurological disorders, cardiovascular diseases, and venous
thromboembolism. Moreover, the growing elderly population
susceptible to these ailments, rising obesity rates, early adoption
of advanced technologies, robust healthcare infrastructure,
increased investments from both governmental and private sectors,
and a surge in regulatory approvals are all contributing to a
positive growth outlook for the North American market.
For example, the CDC's 2023 data reveals that around 33% of
individuals in the US experiencing deep vein thrombosis or
pulmonary embolism are likely to have a recurrence within a decade.
Additionally, the CDC's 2021 report highlights that over 795,000
Americans suffer from strokes annually, with the majority being
first-time occurrences, predominantly ischemic strokes where brain
blood flow is obstructed.
These statistics underscore the escalating prevalence of
cardiovascular and neurological disorders in the region, thereby
bolstering the demand for thrombectomy devices crucial for managing
or treating these conditions. Furthermore, the continuous influx of
regulatory approvals and product launches, such as Stryker
Neurovascular's FDA approval for Trevo NXT Pro Vue Retriever in
August 2021 and February 2020, is propelling market growth. These
strategic advancements are instrumental in augmenting the demand
for thrombectomy devices, thus propelling the North American
thrombectomy devices market during the projected period.
To know more about why North
America is leading the market growth in the thrombectomy
devices market, get a snapshot of the Thrombectomy Devices
Market Outlook
Thrombectomy Devices Market Dynamics
The thrombectomy devices market is experiencing significant
dynamics driven by a multitude of factors including
technological advancements, increasing prevalence of
cardiovascular diseases, and growing awareness about
minimally invasive surgical procedures. Thrombectomy devices
are primarily used to remove blood clots from arteries or veins,
thereby restoring blood flow and preventing potentially
life-threatening conditions such as stroke or pulmonary embolism.
With the aging population and rising incidences of obesity and
sedentary lifestyles, the demand for these devices is on the
rise.
One of the key dynamics shaping the thrombectomy devices market
is the continuous innovation in device design and
technology. Manufacturers are investing heavily in research and
development to introduce advanced thrombectomy devices that offer
improved efficacy, safety, and patient outcomes. This includes the
development of devices with better navigation capabilities,
enhanced suction power, and compatibility with various anatomical
structures.
Moreover, there is a growing trend towards the adoption of
minimally invasive procedures over traditional surgical
methods. Thrombectomy devices play a crucial role in this shift as
they enable physicians to remove blood clots with minimal trauma to
surrounding tissues, reduced risk of complications, and faster
recovery times for patients. As a result, healthcare providers are
increasingly incorporating thrombectomy procedures into
their treatment protocols, driving the demand for these
devices.
Another significant factor influencing the thrombectomy devices
market dynamics is the increasing incidence of cardiovascular
diseases worldwide. Conditions such as ischemic stroke, acute
myocardial infarction, and deep vein thrombosis are becoming more
prevalent, creating a substantial patient pool in need of
thrombectomy interventions. Additionally, the rise in
awareness about the importance of early detection and treatment
of such conditions is fueling the demand for thrombectomy devices
among both healthcare providers and patients.
Furthermore, the thrombectomy devices market is witnessing
consolidation activities as major players seek to strengthen
their market presence through strategic partnerships, mergers,
and acquisitions. This consolidation is aimed at expanding product
portfolios, leveraging complementary technologies, and gaining
access to new geographic markets. As a result, the competitive
landscape of the thrombectomy devices market is evolving
rapidly, with companies vying for market share through innovation,
differentiation, and market expansion strategies. Overall, these
dynamics are expected to continue driving growth in the
thrombectomy devices market in the coming years.
Get a sneak peek at the thrombectomy devices market dynamics @
Thrombectomy Devices Market Dynamics Analysis
Report
Metrics
|
Details
|
Coverage
|
Global
|
Study Period
|
2021–2030
|
Thrombectomy Devices
Market CAGR
|
~5%
|
Key Thrombectomy
Devices Companies
|
Koninklijke Philips
N.V., Terumo Corporation, Medtronic, Boston Scientific Corporation,
Penumbra, Inc., Thrombolex, Imperative Care Inc., Stryker, Argon
Medical Devices Inc., Edwards Lifesciences Corporation, Johnson
& Johnson, BD, phenox GmbH, DSMAREF CO.LTD, Teleflex
Incorporated, AngioDynamics, Abbott, inari Medical, Merit Medical
Systems, Acandis GmbH, among others
|
Thrombectomy Devices Market Assessment
- Thrombectomy Devices Market Segmentation
-
- Thrombectomy Devices Market Segmentation By Product:
Aspiration Thrombectomy Devices, Mechanical Thrombectomy Devices,
Ultrasonic Thrombectomy Devices, and Others
- Thrombectomy Devices Market Segmentation By Application:
Cardiovascular Thrombectomy, Neurovascular Thrombectomy, and
Peripheral Vascular Thrombectomy
- Thrombectomy Devices Market Segmentation By End User:
Hospitals & Clinics, Ambulatory Surgical Centers, and
Others
- Thrombectomy Devices Market Segmentation By Geography:
North America, Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case
Studies, KOL's Views, Analyst's View
Which MedTech key players in the thrombectomy devices market are
set to emerge as the trendsetter explore @ Thrombectomy Devices
Companies
Table of Contents
1
|
Report
Introduction
|
2
|
Executive
summary
|
3
|
Regulatory and Patent
Analysis
|
4
|
Key Factors
Analysis
|
5
|
Porter's Five Forces
Analysis
|
6
|
Thrombectomy Devices
Market Layout
|
7
|
Global Company Share
Analysis – Key 3-5 Companies
|
8
|
Thrombectomy
Devices Market Company and Product
Profiles
|
9
|
Project
Approach
|
10
|
About
DelveInsight
|
Interested in knowing the thrombectomy devices market by 2030?
Click to get a snapshot of the Thrombectomy Devices Market
Trends
Related Reports
Ischemic Stroke Pipeline
Ischemic Stroke Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key Ischemic Stroke companies,
including Athersys, Inc., Tarveda Therapeutics, Lumosa
Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen
Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co.,
Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics
Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere
Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming
Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech,
Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon
Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical,
Pharmazz, among others.
Ischemic Stroke Epidemiology
Ischemic Stroke Epidemiology Forecast – 2032 report
delivers an in-depth understanding of the disease, historical, and
forecasted ischemic stroke epidemiology in the 7MM.
Acute Ischemic Stroke Market
Acute Ischemic Stroke Market Insight,
Epidemiology, and Market Forecast – 2032 report delivers an
in-depth understanding of the market trends, market drivers, market
barriers, and key acute ischemic stroke companies, including
Acticor Biotech, DiaMedica Therapeutics, Lumosa Therapeutics,
Bristol Myers Squibb, Janssen Pharmaceutical, Genentech, Inc.,
Athersy, Healios K.K., NoNO Inc., Bayer, ZZ Biotech, Biogen Inc.,
Revalesio Corporation, AbbVie, TrueBinding, Inc, Silver Creek
Pharmaceuticals, among others.
Acute Ischemic Stroke Pipeline
Acute Ischemic Stroke Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key acute ischemic stroke companies,
including Genentech, Acticor Biotech, DiaMedica
Therapeutics, and NoNO, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/global-thrombectomy-devices-market-to-witness-growth-at-a-cagr-of-5-by-2030--delveinsight-302162758.html